This protocol is judged by an institutional critique board, an unbiased team that critiques any scientific trials involving humans. If a research consists of a Routine I drug, after the board approves the protocol as ethical, the researchers must apply for an investigational new drug (IND) variety with the FDA.Some researchers and companies contem